Bee Venom Potential Key to HIV Cure

Bee venom may be the answer to defeating HIV.

The toxin melittin, a peptide found in bee sting venom, could serve as a prophylactic against HIV when applied prior to sexual activity, according to a new study. This approach could potentially destroy HIV by creating holes in the envelope that surrounds the virus.

Although melittin can kill viruses, it is a cytolytic, which means it can destroy cells by increasing their permeability. Unfortunately, this negatively affects both the virus and important human cells, according to Itech Post.

The results of a study conducted by investigators from Washington University, found that by attaching melittin to complex nanoparticles, it allows the compound to selectively target HIV without affecting non-viral cells.

The investigators infused the nanoparticles with the bee venom toxin. A protective bumper was then added to the nanoparticle’s surface, which allowed it to bounce off normal cells and leave them intact, according to Itech Post.

When the melittin on the nanoparticles fuses with the viral envelope, it forms pore-link attack complexes that rupture the envelope and strips it off the virus, according to Joshua L. Hood, MD, PhD, as reported by Itech Post.

Hood noted that the approach could lead to the development of a vaginal gel that stops HIV transmission, and even an intravenous treatment to help individuals already infected with HIV.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

People who inject drugs may not accurately self-report HIV and antiretroviral drug status when entering an HIV prevention study.
Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses HIV and oncology distinction programs and how these standards bring patients, physicians, and pharmacists together to align care.
Rates of hospital inpatient admissions before and during use of ivacaftor found that overall and cystic fibrosis-related inpatient admissions fell by 55% and 81%, respectively.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.